<DOC>
	<DOC>NCT00535639</DOC>
	<brief_summary>This trial is performed to assess the tolerability of the ALK Tree Tablet in patients with birch pollen induced allergy</brief_summary>
	<brief_title>Tolerability of ALK Tree Tablet</brief_title>
	<detailed_description />
	<criteria>A clinical history of birch pollen induced rhinoconjunctivitis (with or without mild to moderate asthma ) of at least two years prior to trial entry requiring symptomatic treatment during the birch pollen season. Positive Skin Prick Test response to Betula verrucosa Positive specific IgE against Bet v1 FEV1 â‰¥ 70% of predicted value No clinical history of perennial allergic rhinitis and/or asthma caused by an allergen to which the subject is regularly exposed and sensitised No clinical history of significant recurrent acute sinusitis (defined as 2 episodes per year for the last two years all of which required antibiotic treatment) or chronic sinusitis No conjunctivitis, rhinitis or asthma at the screening or randomisation visit No history of anaphylaxis, including anaphylactic food allergy, bee venom anaphylaxis, exercise anaphylaxis or drug induced anaphylaxis No history of angioedema</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2008</verification_date>
	<keyword>Tolerability of ALK Tree Tablet in patients with birch pollen induced allergy</keyword>
</DOC>